(S)-4-[(E)-2-(6-chloro-pyridin-3-yl)-vinyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester | 1374038-35-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (S)-4-[(E)-2-(6-chloro-pyridin-3-yl)-vinyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl (4S)-4-[(E)-2-(6-chloropyridin-3-yl)ethenyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate
• CAS: 1374038-35-3
• 化学式: C₁₇H₂₃ClN₂O₃
• 分子量: 338.834
• InChiKey: DVSQHFCODSBYLW-CFNZNRNTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  51.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-4-[(E)-2-(6-chloro-pyridin-3-yl)-vinyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester 在 铂 氢气 作用下， 以 甲醇 为溶剂， 反应 0.25h， 以to give (S)-4-[2-(6-chloro-pyridin-3-yl)-ethyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (949 mg, 94%) as a colourless oil的产率得到(S)-4-[2-(6-chloro-pyridin-3-yl)-ethyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  DIHYDROOXAZOL-2-AMINE DERIVATIVES

  摘要：

  本发明涉及式I的化合物，其中R1、R2、R3、R4、X、Ar和在此定义的的或其药学上可接受的酸加合盐。式I的化合物对痕量胺相关受体（TAARs）具有良好的亲和力，特别是对TAAR1。这些化合物可用于治疗抑郁症、焦虑症、双相障碍、注意力缺陷多动障碍（ADHD）、与压力有关的疾病、精神疾病如精神分裂症、神经系统疾病如帕金森病、神经退行性疾病如阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用和代谢性疾病如进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和吸收障碍、体温稳态障碍和睡眠和昼夜节律障碍以及心血管疾病。

  公开号：

  US20130345241A1

文献信息

• [EN] DIHYDROOXAZOL-2-AMINE DERIVATIVES<br/>[FR] DÉRIVÉS DE DIHYDROOXAZOL-2-AMINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012059371A1

  公开（公告）日：2012-05-10

  The invention relates to compounds of formula (I) wherein R1 is hydrogen or lower alkyl; R2 is hydrogen or is heteroaryl, optionally substituted by one or more halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, cyano, S-lower alkyl, S(O)-lower alkyl, S(O)2-lower alkyl, C(O)-lower alkyl or C3-6-cycloalkyl; R3 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, cyano, S-lower alkyl, S(O)-lower alkyl, S(O)2-lower alkyl, C(O)-lower alkyl or C3-6-cycloalkyl; R4 is hydrogen or lower alkyl; (A) is phenyl or pyridinyl, wherein the N-atom may be in different positions; X is a bond or CH(CF3)-; Ar is aryl or heteroaryl, optionally substituted by one or more R3; or to a pharmaceutically suitable acid addition salt thereof. It has now been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm and cardiovascular disorders.

  该发明涉及公式(I)的化合物，其中R1是氢或较低的烷基；R2是氢或是杂环芳基，可选择地被一个或多个卤素、较低的烷基、被卤素取代的较低烷基、较低的烷氧基、被卤素取代的较低烷氧基、氰基、S-较低烷基、S(O)-较低烷基、S(O)2-较低烷基、C(O)-较低烷基或C3-6-环烷基取代；R3是氢、卤素、较低烷基、被卤素取代的较低烷基、较低的烷氧基、被卤素取代的较低烷氧基、氰基、S-较低烷基、S(O)-较低烷基、S(O)2-较低烷基、C(O)-较低烷基或C3-6-环烷基；R4是氢或较低烷基；(A)是苯基或吡啶基，其中N原子可能在不同位置；X是键或CH(CF3)-；Ar是芳基或杂环芳基，可选择地被一个或多个R3取代；或其药学上适宜的酸盐。现在发现公式I的化合物对痕量胺相关受体（TAARs）有很好的亲和性，特别是对TAAR1。这些化合物可用于治疗抑郁症、焦虑症、躁郁症、注意力缺陷多动障碍（ADHD）、与压力有关的障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用和代谢障碍，如进食障碍、糖尿病、糖尿病并发症、肥胖、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病。
• Dihydrooxazol-2-amine derivatives
  申请人：Nettekoven Matthias

  公开号：US08673950B2

  公开（公告）日：2014-03-18

  The invention relates to compounds of formula wherein R1, R2, R3, R4, X, Ar, and are defined herein or to a pharmaceutically suitable acid addition salt thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm and cardiovascular disorders.

  本发明涉及式I的化合物，其中R1、R2、R3、R4、X、Ar和在此处定义的N为定义的药学上适宜的酸加盐。式I的化合物对痕量胺相关受体（TAARs），特别是TAAR1具有良好的亲和力。这些化合物可用于治疗抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍（ADHD）、与压力相关的障碍、精神障碍如精神分裂症、神经疾病如帕金森病、神经退行性疾病如阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用和代谢性疾病，如饮食失调、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍和睡眠和昼夜节律障碍以及心血管疾病。
• US8673950B2
  申请人：——

  公开号：US8673950B2

  公开（公告）日：2014-03-18
• DIHYDROOXAZOL-2-AMINE DERIVATIVES
  申请人：Nettekoven Matthias

  公开号：US20120108609A1

  公开（公告）日：2012-05-03

  The invention relates to compounds of formula wherein R 1 , R 2 , R 3 , R 4 , X, Ar, and are defined herein or to a pharmaceutically suitable acid addition salt thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm and cardiovascular disorders.

  本发明涉及以下结构的化合物，其中R1、R2、R3、R4、X、Ar和在此处定义，或其药用合适的酸盐。公式I的化合物对痕量胺相关受体（TAARs）具有良好的亲和力，特别是对于TAAR1。这些化合物可用于治疗抑郁症、焦虑障碍、双相情感障碍、注意力缺陷多动障碍（ADHD）、与压力相关的障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用以及代谢性障碍如进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病。